Epoxygenase Cyp2c44 Regulates Hepatic Lipid Metabolism and Insulin Signaling by Controlling FATP2 Localization and Activation of the DAG/PKCδ Axis
Diabetes · 2024
DOI: 10.2337/db23-0493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Kakali Ghoshal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN. Hauptthemen laut MEDLINE: Cytochrome P450 Family 2, Diglycerides, Insulin, Lipid Metabolism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, BLRD VA, JRF Ortho.
Abstract (Originalsprache)
Cytochrome P450 epoxygenase Cyp2c44, a murine epoxyeicosatrienoic acid (EET)-producing enzyme, promotes insulin sensitivity, and Cyp2c44−/− mice show hepatic insulin resistance. Because insulin resistance leads to hepatic lipid accumulation and hyperlipidemia, we hypothesized that Cyp2c44 regulates hepatic lipid metabolism. Standard chow diet (SCD)-fed male Cyp2c44−/− mice had significantly decreased EET levels and increased hepatic and plasma lipid levels compared with wild-type mice. We showed increased hepatic plasma membrane localization of the FA transporter 2 (FATP2) and total unsaturated fatty acids and diacylglycerol (DAG) levels. Cyp2c44−/− mice had impaired glucose tolerance and increased hepatic plasma membrane–associated PKCδ and phosphorylated IRS-1, two negative regulators of insulin signaling. Surprisingly, SCD and high-fat diet (HFD)-fed Cyp2c44−/− mice had similar glucose tolerance and hepatic plasma membrane PKCδ levels, suggesting that SCD-fed Cyp2c44−/− mice have reached their maximal glucose intolerance. Inhibition of PKCδ resulted in decreased IRS-1 serine phosphorylation and improved insulin-mediated signaling in Cyp2c44−/− hepatocytes. Finally, Cyp2c44−/− HFD-fed mice treated with the analog EET-A showed decreased hepatic plasma membrane FATP2 and PCKδ levels with improved glucose tolerance and insulin signaling. In conclusion, loss of Cyp2c44 with concomitant decreased EET levels leads to increased hepatic FATP2 plasma membrane localization, DAG accumulation, and PKCδ-mediated attenuation of insulin signaling. Thus, Cyp2c44 acts as a regulator of lipid metabolism by linking it to insulin signaling. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.
- Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.
- Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.
- Mass Spectrometry Research Center, Vanderbilt University School of Medicine, Nashville, TN.
- UT Southwestern Medical Center, Dallas, TX.
- Department of Veterans Affairs, Nashville, Nashville, TN.
ORCID-Profile: Ambra Pozzi
Förderung
- NIH HHS
- BLRD VA
- JRF Ortho
- NIDDK NIH HHS
- VA
- Vanderbilt Equipment Grant
- American Diabetes Association
- Department of Veterans Affairs
Zitieren
APA
Ghoshal, K., Luther, J. M., Pakala, S. B., Chetyrkin, S., Falck, J. R., Zent, R., Wasserman, D. H., & Pozzi, A. (2024). Epoxygenase Cyp2c44 Regulates Hepatic Lipid Metabolism and Insulin Signaling by Controlling FATP2 Localization and Activation of the DAG/PKCδ Axis. Diabetes. https://doi.org/10.2337/db23-0493
Vancouver
Ghoshal K, Luther JM, Pakala SB, Chetyrkin S, Falck JR, Zent R, et al. Epoxygenase Cyp2c44 Regulates Hepatic Lipid Metabolism and Insulin Signaling by Controlling FATP2 Localization and Activation of the DAG/PKCδ Axis. Diabetes. 2024. doi:10.2337/db23-0493
BibTeX
@article{Ghoshal2024,
author = {Ghoshal, Kakali and Luther, James M and Pakala, Suman B and Chetyrkin, Sergei and Falck, John R and Zent, Roy and Wasserman, David H and Pozzi, Ambra},
title = {Epoxygenase Cyp2c44 Regulates Hepatic Lipid Metabolism and Insulin Signaling by Controlling FATP2 Localization and Activation of the DAG/PKCδ Axis},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0493}
}
EUVIMED